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Continuous Smoking and
Progression of Arterial Stiffening
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Chisa Matsumoto, MD,* Mari Odaira, MD,* Jiko Yamada, MD,* Masanobu Yoshida, MD,*
Kazuki Shiina, MD,* Mikio Nagata, MD,§ Akira Yamashina, MD*
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Objectives We prospectively and longitudinally determined the effects of smoking on the progression of arterial stiffening
as well as the involvement of inflammation in this process.
Background Smoking is an important avoidable risk factor for cardiovascular disease, and arterial stiffness might be involved
in the pathophysiology. No prospective study has examined the effect of continuous smoking on the age-
associated progression of arterial stiffening.
Methods In 2,054 Japanese subjects (40  8 years of age), brachial-ankle pulse wave velocity (baPWV) and serum
C-reactive protein (CRP) levels were measured at the baseline and the end of a 5- to 6-year follow-up period.
Results The annual rate of change of the baPWV during the study period was significantly greater in the continuous
heavy smokers (11.0  1.9 cm/s/year, n  181) than in the never-smokers (5.5  0.6 cm/s/year, n  1,018).
This difference remained significant even after adjustments for covariates, including age (p  0.05). In continu-
ous smokers (n  493), the mean number of cigarettes smoked/day during the study period showed a signifi-
cant relationship with the changes in baPWV. No significant relationship was found between the change in
baPWV and serum CRP levels.
Conclusions Continuous smoking might accelerate the age-associated progression of structural stiffening of the large- to
middle-size arteries. We also found a dose–response relationship between cigarette consumption and acceler-
ated arterial stiffening. However, we failed to confirm any significant association between the rate of arterial
stiffening and the serum CRP levels in the smokers. (J Am Coll Cardiol 2010;55:1979–87) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.042d
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Drterial stiffness plays a key role in the pathophysiology of
ardiovascular (CV) disease and is recognized as an inde-
endent risk factor for CV disease (1,2). Pulse wave velocity
PWV) is a representative measure of arterial stiffness and
as been used as a marker of not only vascular damage but
lso CV risk (1,3). Several epidemiological studies have
emonstrated that smoking is a major risk factor for
ardiovascular events (4,5). Acute smoking impairs regional
rterial distensibility and increases PWV (6,7), and chronic
mokers exhibit impairments of arterial distensibility and
levated PWV (8,9). However, no prospective study has
rom the *Second Department of Internal Medicine, Tokyo Medical University,
okyo, Japan; †Health Management and Policy, University of Tokyo Graduate
chool of Medicine, Tokyo, Japan; ‡Department of Kinesiology and Health Educa-
ion, University of Texas, Austin, Texas; and the §Health Care Center, Kajima
orporation, Tokyo, Japan. This study was supported in part by a fund from
MRON Health Care (Kyoto, Japan) (donated to Prof. Yamashima).t
Manuscript received October 6, 2009; revised manuscript received December 14,
009, accepted December 17, 2009.etermined whether continuous smoking might accelerate
he progression of arterial stiffening with advancing age and,
f so, whether there might be a dose–response relationship.
oreover, it is not clear whether inflammation, one of the
echanisms underlying the atherogenic action of smoking
4,10), contributes to the progression of arterial stiffening
ttributed to smoking.
Accordingly, the present prospective study was conducted
n a large cohort of middle-age Japanese workers to
etermine: 1) the effect of smoking status on the progression
f arterial stiffening with age; 2) the relationship between
he amount of smoking and the age-associated progression of
rterial stiffening; and 3) involvement of inflammation in the
rogression of arterial stiffening attributed to smoking.
ethods
esign and subjects. This cohort study was initiated on
he employees of a single large construction company in the
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Smoking and Arterial Stiffening May 4, 2010:1979–87year 2000 when annual health
checkups were mandated by the
Occupational Health and Safety
Law. In addition to the evalua-
tion of routine clinical parame-
ters such as blood pressure and
serum cholesterol, the checkup
included atherosclerotic risk fac-
tors and brachial-ankle pulse
wave velocity (baPWV). Mea-
surement of the serum C-reactive
protein (CRP) levels was begun
from the year 2002. Among all
he study subjects, those who were working at the company
eadquarters were invited to undergo follow-up measure-
ents of baPWV and blood and urine examinations from
007 to 2008. Verbal informed consent was obtained from
ll of the study participants before their participation in this
tudy. The study was conducted with the approval of the
thical Guidelines Committee of Tokyo Medical Univer-
ity. Some related data have been presented elsewhere (11).
All the participants were provided feedback on the results
f the annual health checkups. Along with other lifestyle
odification recommendations, smoking cessation was rec-
mmended to the subjects who were identified as smokers.
ubjects with positive atherosclerotic risk factors (body mass
ndex [BMI] 25 kg/m2, triglyceride 150 mg/dl, high-
ensity lipoprotein [HDL] cholesterol 40 mg/dl, fasting
lasma glucose 126 mg/dl, blood pressure 140/90 mm
g, and/or total cholesterol 240 mg/dl) were advised to
isit the health care center within the construction company
nd were provided with advice with regard to therapeutic
ifestyle modifications by health professionals, in accordance
ith the guidelines of the Japanese Societies of Atheroscle-
osis, Diabetes Mellitus, and Hypertension (12–17). Sub-
ects requiring medications were prescribed appropriate
rugs at either the health care center or at other clinics.
ach patient was given the freedom to choose his/her own
octor for such treatment.
Subjects with the following conditions were excluded
rom the present study: 1) unusually low or unreliable
aPWV values (due to ankle/brachial systolic blood pressure
ndex [ABI] 0.95, atrial fibrillation, and/or regular hemo-
ialysis) (11); and 2) serum CRP levels 10.0 mg/l (as the
onventional clinical cutoff point for inflammation) (18).
A total of 2,357 subjects who were working at the
ompany headquarters in the year 2002 were enrolled in the
tudy protocol. Of these, 2,175 subjects were successfully
ollowed up until 2007 to 2008, and 182 were excluded
ecause of the lack of complete datasets (n  18) and
issing follow-up data (n  164), due to moving of the
ubjects from the company headquarters to branch offices,
ayoffs, retirement, and so forth. Of the 2,175 subjects, 79
ere excluded for the following reasons: ABI 0.95 (n 
7); atrial fibrillation (n  12); serum CRP 10 mg/l (n 
Abbreviations
and Acronyms
ABI  ankle-brachial
pressure index
ANOVA  analysis of
variance
baPWV  brachial-ankle
pulse wave velocity
CRP  C-reactive protein
CV  cardiovascular
PWV  pulse wave velocity8; 2 of them also had an ABI 0.95); and hemodialysis qn  2). Finally, 2,096 subjects were successfully enrolled
or the 5- to 6-year follow-up study.
easurement of the baPWV. Brachial-ankle pulse wave
elocity was measured with a volume-plethysmographic
pparatus (Form/ABI, Colin Company, Ltd., Komaki,
apan), as previously described (11,19). Briefly, electrocar-
iographic electrodes were placed on both wrists, and a
icrophone for the phonocardiogram was attached on the
eft chest. Electrocardiograms and phonocardiograms were
sed to provide timing markers for the device. Occlusion
uffs, which were connected to both the plethysmographic
nd oscillometric sensors, were tied around both the upper
rms and ankles while the subjects were in the supine
osition. The brachial and post-tibial arterial pressures were
easured by the oscillometric sensor. Ten-second record-
ngs of the brachial and post-tibial arterial pressure wave-
orms recorded by the plethysmographic sensor were stored.
he measurements were conducted after the subjects had
ested for at least 5 min in the supine position in an
ir-conditioned room (maintained at 24°C) allocated exclu-
ively for this study. Blood pressure was determined by the
scillometric sensor, and heart rate was also simultaneously
ecorded during the measurement of the baPWV. The
nterobserver and intraobserver coefficients of variation for
aPWV measurements were 8% and 10% in our previous
tudy (19).
For the analyses, the mean values of the baPWV and
lood pressure measured on both sides (i.e., [value measured
n the right side value measured on the left side] / 2) were
sed. The annual rate of change in the baPWV during the
tudy period was calculated as: value at the final examination
inus value at the baseline examination divided by the
uration of follow-up (years).
aboratory measurements. Serum concentrations of tri-
lyceride, total cholesterol, HDL-cholesterol, creatinine,
nd CRP as well as plasma glucose concentration were
easured with standard enzymatic methods (Falco Biosys-
ems Company, Ltd., Tokyo, Japan) (20). All the blood
amples were obtained in the morning, after the patients
ad fasted overnight.
lood pressure measurement. Blood pressure was mea-
ured in an office setting with the subjects in the seated
osition by the conventional cuff method with a mercury
phygmomanometer. Measurements were obtained twice
fter the subjects had rested for at least 5 min, and the mean
f the 2 measurements was reported.
moking status. Smoking status of the subjects (i.e.,
ever-smoker, former smoker, current smoker) were as-
essed with a questionnaire. Current and former smokers
ere requested to provide an average number of cigarettes
moked/day and the duration (number of years) of smoking.
he subjects were classified into 5 different categories on the
asis of their responses at the baseline and final examina-
ions; never smokers (who had no history of smoking),
ormer smokers (who had a past history of smoking),
uitters (who were current smokers in the baseline survey
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May 4, 2010:1979–87 Smoking and Arterial Stiffeningnd former smokers in the final survey), continuous light-
o-moderate smokers (who continued to smoke 20 ciga-
ettes/day at the time of both the baseline and the final
urveys), and continuous heavy smokers (who continued to
moke 20 cigarettes/day at both the baseline and the final
urvey) (21). The questionnaire was not designed to assess
he reason why former smokers quit smoking or the exact
ate of quitting smoking. Starters or relapsers (who were
ever-smokers/former smokers at the baseline survey and
hanged their smoking status to current smokers at the final
urvey) were excluded, because of a smaller number of
ubjects in this group (n  42) and the difficulty in precisely
ssessing their smoking history.
We estimated the average number of cigarettes smoked/
ay (amount of smoking) in the subjects who continued to
moke throughout the study period, to examine the dose–
esponse relationship between the amount of smoking and
he rate of changes in baPWV. The average number of
igarettes smoked/day during the study period was calcu-
ated by the sum of the mean daily number of cigarettes
moked reported at each annual checkup divided by the
uration of follow-up (in years).
tatistical analysis. Data were expressed as mean  SD
nless otherwise indicated. The differences in the continu-
us variables across the 5 smoker categories were assessed by
-way analysis of variance (ANOVA), and the differences in
he measured values between the baseline and final exami-
ations were assessed by the paired t test. In the ANOVA,
cheffe’s test was applied for post-hoc multiple comparisons.
The categorical variables were categorized as follows: sex
female 0 and male 1); alcohol intake (nondrinker 0,
ight-to-moderate drinker [ethanol consumption, 1 to 29
/day]  1, and heavy drinker [ethanol consumption, over
0 g/day]  2); medication for coronary heart disease,
troke, hypertension, diabetes mellitus, and/or dyslipidemia
for each medication: no medication  0, and taking
edication 1); and persistent elevation of the serum CRP
evel during the study period (i.e., serum CRP levels in the
ighest tertile range at both the baseline and final exami-
ations) (no persistent elevation  0, and persistent eleva-
ion  1). Pearson’s chi-square test was applied for assess-
ent of the differences in the categorical variables across the
smoking status categories (post-hoc comparisons among
ubgroups were not conducted). McNemar’s nonparametric
est was applied for assessment of the differences in the
edications prescribed between the baseline and final ex-
minations, and Friedman’s nonparametric test was applied
or assessment of the differences in the amount of alcohol
ntake between the baseline and final examinations.
In the general linear model analyses, the annual rate of
hange in baPWV during the study period was entered as a
ependent variable, the 5 smoker categories were entered as
fixed factor, and others were entered as covariates for
djustment. Two different adjustment models were applied.
n Model 1, the covariates for adjustments were the baseline
alues of factors already known to be linked to arterial 2tiffness and/or atherosclerosis (1,3,11,19,20) (i.e., age; sex;
ody mass index; alcohol intake; mean blood pressure; heart
ate; serum total cholesterol; serum HDL-cholesterol; se-
um triglyceride; serum creatinine; fasting blood glucose;
nd medication for coronary heart disease, stroke, hyper-
ension, diabetes mellitus, and/or dyslipidemia). In Model
, the covariates for adjustments were all the variables
ncluded in Model 1 plus the changes in these variables
except for sex) during the study period. In the analysis
ithout adjustments for covariates, Scheffe’s test was ap-
lied for post hoc multiple comparisons. In the analysis with
djustments for covariates (Model 1 and 2), Bonferroni’s
est was applied for post hoc pair-wise comparisons.
We specifically tested the association between serum
RP and the annual rate of changes in baPWV, because
RP might mediate the effect of smoking on the progres-
ion of arterial stiffening. Because serum CRP levels were
kewed, the analyses were conducted with and without
og-transformation of serum CRP levels. Multivariate linear
egression analysis with the aforementioned adjustments
Model 1 and 2) were used to test the influence of serum
RP as well as persistently elevated serum CRP on the
nnual rate of changes in baPWV. Finally, we conducted
ultivariate regression analysis with the Model 1 and 2
djustments mentioned in the preceding text among con-
inuous smokers, to test the dose–response relationship
etween the amount of smoking and the change in baPWV.
All the analyses were conducted with the IBM/SPSS
oftware (version 17.0J for Windows, IBM/SPSS, Inc.,
hicago, Illinois). The p values 0.05 were considered to
enote statistical significance.
esults
mong the 2,096 subjects, 42 were identified as relapsers
nd therefore were excluded from the analyses. The data of
he remaining 2,054 subjects (age 40  8 years, 1,648 men
nd 406 women) were included for the analyses. The
ollow-up period (study duration) was 6 years for 1,734 of
he 2,054 subjects and 5 years for the remaining 320
ubjects.
Table 1 shows the clinical characteristics and changes in
he body measurements during the study period in the 5
moking categories. The paired t test demonstrated that
aPWV increased significantly during the study period in all
smoking categories. The ANOVA with Scheffe’s test
emonstrated that the baPWV at the baseline examination
as higher in the quitters and continuous heavy smokers
han in the never-smokers. The mean age at the baseline
xamination was higher in the former smokers and contin-
ous heavy smokers than in the other 3 categories of
mokers. However, the group differences in baPWV re-
ained significant even after the adjustments for covariates,
ncluding age (p  0.05).
We examined, in the entire subject population (n ,054), whether continuous smoking could influence the
Changes in Selected Subjects’ Characteristics During the Study Period (n  2,054)Table 1 Changes in Selected Subjects’ Characteristics During the Study Period (n  2,054)
Never (n  1,018) Former (n  327) Quitter (n  181) Moderate (n  347) Heavy (n  181)
Parameter Baseline Final Baseline Final Baseline Final Baseline Final Baseline Final
Male/female 697/321 — 303/24 — 160/21 — 308/39 — 180/1 —
Age (yrs) 39 8 — 43 8* — 41 8† — 40 8† — 44 8*‡§ —
BMI (kg/m2) 22.7 3.3 22.9 3.5 23.9 3.1* 24.0 3.0* 23.6 3.2* 24.0 3.5* 23.3 2.9 23.5 2.9 24.6 3.4*§ 24.3 3.2*
Alcohol (non/mod/hvy) 263/723/32 244/717/57 47/251/29 37/247/43 23/139/19 24/137/20 52/270/25 30/117/34 51/239/57 29/112/40
Systolic BP (mm Hg) 120 15 120 15 125 15* 125 15* 124 15* 125 14* 123 14 128 15 122 14*§ 126 15*
Diastolic BP (mm Hg) 73 11 75 11 77 12* 77 10* 75 11 78 11* 75 11 77 11 75 11* 77 11
Heart rate (beats/min) 63 9 66 9 63 10 65 10 64 10 65 10 65 9 68 10 65 9*†‡§ 67 10*†‡§
Total-C (mmol/l) 5.1 0.8 5.4 0.8 5.3 0.9* 5.5 0.8 5.1 0.8 5.5 0.8 5.2 0.9 5.3 0.9 5.3 0.9 5.4 0.9
Triglyceride (mmol/l) 1.0 0.8 1.1 0.8 1.4 1.1* 1.5 1.0* 1.5 1.0* 1.5 0.9* 1.4 1.1* 1.5 1.1* 1.9 2.0*†‡§ 1.8 1.6*†§
HDL-C (mmol/l) 1.6 0.4 1.8 0.5 1.6 0.4* 1.7 0.5* 1.5 0.4* 1.7 0.5 1.5 0.4*† 1.6 0.4*† 1.4 0.3*†‡§ 1.5 0.4*†‡§
Glucose (mmol/l) 4.9 0.6 5.0 0.7 5.2 1.0* 5.1 0.7 5.1 1.0 5.2 1.6* 5.0 0.4 5.0 0.6‡ 5.4 1.5*†‡§ 5.2 1.0*§
Creatinine (mol/l) 58.7 6.9 60.0 11.3 60.6 6.9* 63.2 9.4* 59.7 7.2 62.4 11.1* 59.5 6.5 60.5 8.6† 58.8 6.1 62.0 9.8
CRP (mg/l) 0.8 1.1 0.6 1.0 0.9 1.2 0.8 1.2 1.0 1.5 0.9 1.2 0.8 1.3 0.9 1.3 1.2 1.5* 1.1 1.4*§
ElevCRP 143 (14) — 54 (17) — 37 (20) — 58 (17) — 62 (34) —
baPWV (cm/s) 1,225 179 1,258 193 1,306 207* 1,343 211* 1,311 213* 1,340 203* 1,274 187* 1,315 210* 1,334 209*§ 1,399 233*§
CHD 2 8 4 9* 0 2 1 2 0 2
CBVD 0 3 0 5 0 1 0 0 1 1
Medication (%)
For hypertension 33 (3.2) 90 (8.8) 22 (6.7)* 44 (13.5) 7 (3.9) 20 (11.1) 15 (4.3) 33 (9.5) 11 (6.1) 25 (13.8)
For diabetes 5 (0.4) 18 (1.8) 5 (1.5) 10 (3.1) 2 (1.1) 6 (3.3) 2 (0.6) 6 (1.7) 5 (2.8) 10 (5.5)
For dyslipidemia 13 (1.3) 41 (4.0) 7 (2.1) 12 (3.8) 2 (1.1) 5 (2.8) 3 (0.8) 14 (4.0) 5 (2.8) 11 (6.1)
Values are n, mean SD, or n (%). *p 0.05 versus Never; †p 0.05 versus Former; ‡p 0.05 versus Quitter; §p 0.05 versus Moderate (assessed by 1-way analysis of variance with post hoc multiple comparisons by Scheffe’s test). p 0.05 versus Baseline (assessed
by paired t test for continuous variables, by Friedman’s nonparametric test for alcohol intake, and McNemar’s nonparametric test for medications).
baPWV brachial-ankle pulse wave velocity; BMI body mass index; BP blood pressure; C serum cholesterol; CBVD cerebrovascular disease; CHD coronary heart disease; CRP serum C-reactive protein level; ElevCRP persistently elevated serum CRP levels
during the study period; Former former smokers; Heavy smokers who continued to smoke20 cigarettes/day during the study period; hvy heavy drinker (ethanol intake,30 g/day); mod light-to-moderate drinker (ethanol intake, 1 to 29 g/day); Moderate smokers
who continued to smoke 20 cigarettes/day during the study period; Never  never-smokers; non  nondrinker; Quitter  subjects who quit smoking during the study period.
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May 4, 2010:1979–87 Smoking and Arterial Stiffeningate of progression in arterial stiffening with advancing age.
igure 1 shows the crude and adjusted values of the annual
ate of increase in baPWV during the study period across
he 5 different smoker categories. In Figure 1, the upper
anel presents the crude comparison with the Scheffe’s
ethod. Continuous heavy smokers were significantly dif-
erent from never-smokers in the pair-wise comparison.
ontinuous heavy smokers were also significantly different
rom other 4 groups in the contrast comparison. In an
djusted model (Model 1), post-hoc pair-wise comparisons
y Bonferroni’s test demonstrated that the rate of arterial
tiffening was significantly greater in the continuous heavy
mokers than in the never-smokers and former smokers
Fig. 1, middle panel). In further adjustment including
hanging scores (Model 2), the rate of arterial stiffening was
ignificantly greater in the continuous heavy smokers than
n the never-smokers, former smokers, and quitters (Fig. 1,
ower panel). Because there were fewer women than men in
he present study, the same analyses were conducted with
nly male data. The same results shown in Figure 1 were
btained even if we confined the analyses to men only (n 
,648) (data not shown).
As shown in Table 1, ANOVA with the Scheffe’s test
emonstrated that the serum CRP concentrations were
reater in the continuous heavy smokers than in the never-
mokers at both the baseline and final examinations. The
esults of the Pearson’s chi-square test demonstrated that
he prevalence of subjects with persistently elevated serum
An
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FORMER   
n=327     
QUITT
n=18
NEVER
n=1018             
Figure 1 Mean ( SEM) Annual Rate of Increases in baPWV D
The details of the covariates in Model 1 and 2 are described in the text. *p  0.0
¶p  0.05 versus Quitter, in Bonferroni’s test. baPWV  brachial-ankle pulse wav
cigarettes/day during the study period; Moderate  subjects who continued to sm
subjects who quit smoking during the study period.RP during the study period (as defined in the statistical
nalysis section) differed among the 5 smoking categories
i.e., the prevalence rate in the continuous smokers was
4%, whereas that in the never-smokers was 14%).
Univariate analyses in the entire subject population (n 
,054) revealed that the annual rate of increase in baPWV
as not significantly associated with baseline serum CRP
evels, baseline log-transformed serum CRP levels, changes
n serum CRP levels during the study period, and changes in
og-transformed serum CRP levels. The annual rate of
ncrease in baPWV was significantly correlated only with
ersistent elevations in serum CRP levels (Table 2). How-
ver, in the multivariate linear regression analysis with
djustments using Model 1 and Model 2, the relationships
etween the annual rate of increases in baPWV and the
Crude
Adjusted Model 1
Adjusted Model 2
†‡
*
†‡
DERATE
n=347
HEAVY
n=181
the Study Period Across the 5 Different Smoker Categories
us Never, in Scheffe’s test. †p  0.05 versus Never; ‡p  0.05 versus Former;
ity; Former  former smokers; Heavy  subjects who continued to smoke 20
20 cigarettes/day during the study period; Never  never smokers; Quitter 
nivariate Analyses Showing Relations Between thenual Rate of Changes in baPWV During Study Periodd Param ters Related to Serum CRP Conc ntration
Table 2
Univari t Analyses Sh wing Relations Between the
Annual Rate of Changes in baPWV During Study Period
and Parameters Related to Serum CRP Concentration
Variable Pearson’s r Value p Value
Serum CRP at baseline 0.02 0.45
Log serum CRP at baseline 0.02 0.28
Serum CRP 0.01 0.75
Log serum CRP 0.01 0.69
Persistently elevated serum CRP 0.05 0.03
aPWV  brachial-ankle pulse wave velocity; CRP  C-reactive protein; Serum CRP  absolute
hanges (mg/l) in serum CRP level (value at the final examination – value at the baseline
xamination); Persistently elevated serum CRP  subjects with persistently elevated CRP levels
uring the study period (no  0 and yes  1).MOER 
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Smoking and Arterial Stiffening May 4, 2010:1979–87ersistent elevation of the serum CRP did not reach
tatistical significance (Table 3).
The completed questionnaire on the smoking status was
vailable for all the study years (except in year 2005) in 493
f the 528 continuous smokers. On univariate analyses,
here was a significant positive relationship between the
nnual rate of increases in baPWV and the number of
igarettes smoked/day (r  0.19, p  0.01). Furthermore,
ultivariate linear regression analyses with adjusted Model
and Model 2 demonstrated that the number of cigarettes
moked/day was a significant independent correlate with the
nnual rate of increases in baPWV (Table 4). The results
ere essentially the same when the sample was limited only
o men (n  480) (data not shown).
iscussion
o the best of our knowledge, the present study was the first
rospective study to examine the effects of smoking status as
ell as the amount of smoking on the rate of progression in
rterial stiffening with aging. The results revealed that the
nnual rate of increases in baPWV was significantly greater
n the continuous heavy smokers than in the never-smokers.
hese findings suggest that continuous heavy smoking
ccelerates the age-associated progression of stiffening of
he large conduit arteries and could contribute to the
ge-related increases in CV disease.
A dose–response relationship between cigarette con-
umption and risks of CV events has been reported (22–24).
aldassarre et al. (23) described, on the basis of the results
f their cross-sectional study, the existence of a significant
elationship between the amount of smoking and the
everity of carotid atherosclerosis, as assessed by ultrasound
xamination. The present subanalysis, in which information
bout the number of cigarettes smoked/day was successfully
btained each year (except year 2005) throughout the study
eriod, demonstrated a significant relationship between the
umber of cigarettes smoked/day and the annual rate of
hanges in baPWV. These results suggest the existence of a
ose–response relationship between the amount of continuous
moking and age-associated accelerations of arterial stiffening.
Smoking is thought to be involved in the initiation and
rogression of atherosclerosis via several different mecha-
isms (4,10,25), and some studies have suggested the
nvolvement of inflammation in the accelerated progression
f arterial stiffening in smokers (3,20). In the present study,
erum CRP levels were higher in the continuous smokers
han in the never-smokers. Although persistently elevated
erum CRP levels had a significant association with the
rogression of arterial stiffening on the basis of the univar-
ate analyses, such associations did not reach statistical
ignificance when the multivariate linear regression model
as applied. Serum CRP is a marker of systemic inflam-
ation but not a robust marker of vascular inflammation26). Recently, Schumacher et al. (27) suggested that CRP eoes not have a causal role in the progression of arterial
tiffening. Thus, further studies are needed to determine the
ontribution of smoking-related vascular inflammation to
he progression of arterial stiffening.
Increased aortic stiffness acts as a CV risk factor via
everal different mechanisms, including increased cardiac
fterload, impaired coronary blood flow, increased arterial
all stress, and microvascular damage (1–3). Carotid-
emoral PWV is the most established index for assessment
f the aortic stiffness (1,3), but baPWV has been increas-
ngly used in the research and clinical settings because its
easurement is extremely simple, allowing repeated mea-
urements in a large number of study subjects. Although
aPWV is a marker of stiffness of both large and middle-
ized arteries (11,19), baPWV demonstrates a close corre-
ation not only with carotid-femoral PWV (28) but also
ith aortic PWV, as assessed by a direct catheter-method
19). Furthermore, increased baPWV has been shown as a
arker of prognosis in subjects with acute coronary syn-
rome and end-stage renal disease (29,30).
If continuous smoking itself was a significant determinant
f the progression of arterial stiffening, baPWV at the
aseline examination should be greater in the continuous
eavy smokers than in the former smokers. However,
aseline baPWV was not different between the 2 groups.
he precise explanation for this apparent discrepancy is
nknown. Part of the reason might be related to the
uestionnaire used to evaluate the smoking status. Several
tudies have suggested that questionnaire surveys to deter-
ine the smoking status might underestimate the preva-
ence of smoking (31), and no biochemical confirmation of
uitting smoking was carried out in the present study. An
lternative explanation is that the effects of chronic smoking
n arterial stiffness would persist for a long time after the
moking cessation. Indeed, 5 to 6 years of no smoking did
ot induce any noticeable arterial de-stiffening in the former
mokers or in the quitters. Jatoi et al. (8) suggested, on the
asis of the results of their cross-sectional study, that it
ight take more than 1 decade to reverse the smoking-
nduced arterial stiffening. Another possibility is that smok-
ng is simply one of the various factors that affect arterial
tiffening. Indeed, after the adjustments for a number of
onfounders (Model 1), the association between arterial
tiffening and cigarette smoking remained statistically sig-
ificant but weakened. This would suggest that other
ertinent factors (e.g., blood pressure) might be exerting
mportant influences on arterial stiffening.
There are several study limitations in the present study
hat should be emphasized. First, the subjects were relatively
oung (mean age of approximately 40 years), and there were
ewer women than men. Therefore, the confirmation of the
resent findings in older subjects and/or in women is
arranted. Second, the effects of passive smoking were notxamined in the present study.
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May 4, 2010:1979–87 Smoking and Arterial Stiffeningultivariate Linear Regression Analyses Showing Association Between the Annual Ratef Changes in baPWV During Study Period and Persi tently Eleva ed Serum CRPTable 3 Multivariate Linear Regres ion Analyse Show ng Association Between the Annual Rateof Changes in baPWV During Study Period and Persistently Elevated Serum CRP
Independent Variables Nonstandardized Coefficient (95% CI) Standardized Coefficient p Value
Model 1*
Persistently elevated CRP (no  0; yes  1) 2.226 (0.268 to 4.720) 0.039 0.08
Age (yrs) 0.788 (0.657 to 0.918) 0.292 0.01
Sex (female  0; male  1) 1.651 (1.215 to 4.516) 0.030 0.259
BMI (kg/m2) 0.860 (0.505 to 1.216) 0.128 0.01
Alcohol intake (none  0; moderate  1; heavy  2) 3.84 (2.314 to 1.545) 0.009 0.696
Mean BP (mm Hg) 0.598 (0.699 to0.497) 0.335 0.01
Heart rate (beats/min) 5.017 102 (0.157 to 0.056) 0.021 0.355
Total cholesterol (mmol/l) 1.352 (2.550 to0.153) 0.054 0.027
HDL-cholesterol (mmol/l) 0.328 (3.398 to 2.741) 0.006 0.834
Triglycerides (mmol/l) 9.751 102 (1.118 to 0.923) 0.005 0.851
Creatinine (mol/l) 0.162 (0.308 to 0.015) 0.051 0.031
Glucose (mmol/l) 2.440 102 (1.350 to 1.399) 0.001 0.972
Medication CHD (no  0; yes  1) 0.133 (15.546 to 15.279) 0.001 0.986
Medication CBVD (no  0; yes  1) 30.821 (72.569 to 10.927) 0.031 0.148
Medication HT (no  0; yes  1) 2.072 (6.863 to 2.719) 0.019 0.396
Medication DM (no  0; yes  1) 2.311 (9.077 to 13.739) 0.010 0.689
Medication dyslipidemia (no  0; yes  1) 6.495 (1.171 to 14.162) 0.036 0.097
Constant 28.715 (13.998 to 43.432) 0.01
Model 2†
Persistently elevated CRP (no  0; yes  1) 1.474 (0.631 to 3.578) 0.026 0.170
Age (yrs) 0.561 (0.448 to 0.674) 0.208 0.01
Sex (female  0; male  1) 1.334 (4.042 to 1.375) 0.024 0.334
BMI (kg/m2) 0.163 (0.142 to 0.467) 0.024 0.295
Alcohol intake (none  0; moderate  1; heavy  2) 0.488 (2.267 to 1.292) 0.011 0.591
Mean BP (mm Hg) 0.162 (0.258 to0.067) 0.091 0.01
Heart rate (beats/min) 0.101 (0.004 to 0.198) 0.043 0.042
Total cholesterol (mmol/l) 0.982 (2.068 to 0.103) 0.039 0.076
HDL-cholesterol (mmol/l) 0.625 (3.260 to 2.009) 0.011 0.642
Triglycerides (mmol/l) 1.049 (0.008 to 2.089) 0.053 0.048
Creatinine (mol/l) 5.792 102 (0.184 to 0.069) 0.018 0.369
Glucose (mmol/l) 0.256 (1.723 to 1.211) 0.010 0.732
Medication CHD (no  0; yes  1) 5.547 (7.384 to 18.749) 0.015 0.400
Medication CBVD (no  0; yes  1) 25.240 (60.311 to 9.832) 0.026 0.158
Medication HT (no  0; yes  1) 2.262 (6.425 to 1.901) 0.021 0.287
Medication DM (no  0; yes  1) 3.695 (6.464 to 13.855) 0.016 0.476
Medication dyslipidemia (no  0; yes  1) 5.847 (0.626 to 12.319) 0.032 0.077
BMI (absolute value) 0.395 (0.621 to0.169) 0.072 0.01
Alcohol intake (categories) 1.692 (0.157 to 3.541) 0.035 0.073
Mean BP (absolute value) 1.231 (1.125 to 1.337) 0.481 0.01
Heart rate (changes in absolute value) 0.495 (0.384 to 0.606) 0.176 0.01
Total cholesterol (absolute value) 3.432 102 (0.003 to 0.071) 0.041 0.069
HDL-cholesterol (absolute value) 3.503 103 (0.053 to 0.123) 0.017 0.436
Triglycerides (absolute value) 1.761 102 (0.006 to 0.030) 0.068 0.01
Creatinine (absolute value) 6.821 (1.420 to 15.061) 0.033 0.105
Glucose (absolute value) 4.007 102 (0.105 to 0.025) 0.026 0.227
Medication CBVD (categories) 2.756 (5.972 to 11.484) 0.011 0.536
Medication HT (categories) 3.961 (7.663 to0.259) 0.043 0.036
Medication DM (categories) 3.623 (2.987 to 10.232) 0.022 0.283
Medication dyslipidemia (categories) 4.094 (0.947 to 9.135) 0.030 0.111
Constant 14.374 (42.813 to 14.064) 0.321
ultivariate linear regression analyses showing the association between the annual rate of changes in baPWV during the study period (in centimeters/second/year; dependent variable) and persistently
levated serum CRP with adjustments using the 2 different models (n 2,054). *R2 0.116: adjustments for the baseline values of factors known to be linked to arterial stiffness and/or atherosclerosis;
R2  0.388: adjustments for the baseline values as well as changing scores of factors known to be linked to arterial stiffness and/or atherosclerosis.
CI confidence interval; Persistently elevated serum CRP subjects with persistent elevation of the serum CRP levels during the study period categorized into the highest tertile of the serum CRP level;
P  blood pressure; HT  hypertension; DM  diabetes mellitus;   absolute changes during the study period (value at the final examination  value at the baseline examination); other abbreviations
s in Table 1.
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Smoking and Arterial Stiffening May 4, 2010:1979–87ultivariate Linear Regression Showing the Relationship Between the Annual Ratef Changes in baPWV During Study Period and the Number of Cigarettes Smoked/DayTable 4 Multivariate Linear Regression Showing t e Relationship Between the Annual Rateof Changes in baPWV During Study Period and the Number of Cigarettes Smoked/Day
Independent Variables Nonstandardized Coefficient (95% CI) Standardized Coefficient p Value
Model 1*
Cigarettes/day, n 0.366 (0.144 to 0.588) 0.154 0.01
Age (yrs) 0.708 (0.436 to 0.981) 0.254 0.01
Sex (female  0; male  1) 2.349 (5.821 to 10.520) 0.028 0.572
BMI (kg/m2) 0.856 (0.109 to 1.602) 0.115 0.025
Alcohol Intake (none  0; moderate  1; heavy  2) 3.716 (7.784 to 0.352) 0.083 0.073
Mean BP (mm Hg) 0.501 (0.713 to0.290) 0.266 0.01
Heart rate (beats/min) 4.584 102 (0.268 to 0.177) 0.019 0.686
Total cholesterol (mmol/l) 0.615 (3.023 to 1.792) 0.024 0.616
HDL-cholesterol (mmol/l) 5.875 103 (6.681 to 6.693) 0.001 0.999
Triglycerides (mmol/l) 0.397 (2.050 to 1.255) 0.024 0.637
Creatinine (mol/l) 0.158 (0.479 to 0.163) 0.044 0.335
Glucose (mmol/l) 1.508 (4.162 to 1.145) 0.063 0.265
Medication CHD (no  0; yes  1) 51.976 (98.396 to5.557) 0.102 0.028
Medication CBVD (no  0; yes  1) 39.509 (85.608 to 6.591) 0.078 0.093
Medication HBP (no  0; yes  1) 2.545 (12.382 to 7.293) 0.023 0.611
Medication DM (no  0; yes  1) 8.707 (12.539 to 29.953) 0.045 0.421
Medication dyslipidemia (no  0; yes  1) 24.949 (6.889 to 43.010) 0.129 0.01
Constant 23.247 (8.746 to 55.239) 0.154
Model 2†
Cigarettes/day, n 0.292 (0.111 to 0.473) 0.123 0.01
Age (yrs) 0.550 (0.324 to 0.776) 0.197 0.01
Sex (female  0; male  1) 0.418 (7.493 to 6.657) 0.005 0.908
BMI (kg/m2) 0.277 (0.342 to 0.896) 0.037 0.380
Alcohol intake (none  0; moderate  1; heavy  2) 3.016 (6.579 to 0.546) 0.068 0.097
Mean BP (mm Hg) 5.980 102 (0.248 to 0.129) 0.032 0.533
Heart rate (beats/min) 9.769 102 (0.097 to 0.292) 0.041 0.324
Total cholesterol (mmol/l) 1.113 (3.208 to 0.982) 0.044 0.297
HDL-cholesterol (mmol/l) 2.353 (7.957 to 3.251) 0.037 0.410
Triglycerides (mmol/l) 0.257 (1.405 to 1.918) 0.016 0.762
Creatinine (mol/l) 0.122 (0.400 to 0.156) 0.034 0.389
Glucose (mmol/l) 0.729 (2.270 to 3.278) 0.030 0.633
Medication CHD (no  0; yes  1) 36.058 (73.785 to 1.668) 0.071 0.061
Medication CBVD (no  0; yes  1) 32.946 (71.422 to 5.531) 0.065 0.093
Medication HT (no  0; yes  1) 4.619 (12.800 to 3.563) 0.043 0.268
Medication DM (no  0; yes  1) 3.669 (23.420 to 16.082) 0.019 0.715
Medication dyslipidemia (no  0; yes  1) 20.760 (6.060 to 35.459) 0.107 0.01
BMI (absolute value) 0.292 (0.766 to 0.181) 0.049 0.225
Alcohol intake (categories) 3.166 (0.485 to 6.817) 0.064 0.089
Mean BP (absolute value) 1.284 (1.067 to 1.501) 0.490 0.01
Heart rate (absolute value) 0.637 (0.394 to 0.879) 0.205 0.01
Total cholesterol (absolute value) 1.764 103 (0.078 to 0.075) 0.002 0.964
HDL-cholesterol (absolute value) 7.778 102 (0.110 to 0.266) 0.033 0.417
Triglycerides (absolute value) 1.180 102 (0.008 to 0.031) 0.057 0.237
Creatinine (absolute value) 5.973 (12.455 to 24.400) 0.025 0.524
Glucose (absolute value) 5.978 102 (0.077 to 0.196) 0.041 0.389
Medication CBVD (categories) 8.613 (16.5622 to 33.7886) 0.024 0.502
Medication HT (categories) 2.864 (11.010 to 5.282) 0.029 0.490
Medication DM (categories) 5.966 (17.997 to 6.064) 0.042 0.330
Medication Dyslipidemia (categories) 1.965 (11.332 to 7.401) 0.015 0.680
Constant 14.374 (42.813 to 14.064) 0.321
ultivariate linear regression showing the relationship between the annual rate of changes in brachial-ankle pulse wave velocity during the study period (in centimeters/second/year) and the number of
igarettes smoked/day with adjustments using the 2 different models (n 493 involving continuous smokers whose questionnaire was available for all the study years). *R2 0.161: adjustments for the
aseline values of factors known to be linked to arterial stiffness and/or atherosclerosis. †R2 0.475: adjustments for the baseline values as well as changing scores of factors known to be linked to arterial
tiffness and/or atherosclerosis.
Abbreviations as in Tables 1 and 3.
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he present study was the first prospective study to suggest
hat continuous smoking could accelerate the age-associated
rogression of structural stiffening of the large- to middle-
ized arteries. Our findings also support a dose–response
elationship between cigarette consumption and accelerated
rterial stiffening. The elevated serum CRP levels associated
ith continuous smoking do not seem to be directly
ssociated with the acceleration of arterial stiffening in
ontinuous smokers.
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